phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

As we celebrate Rare Disease Day, it is important to not only reflect on how far we have come in tackling these devastating and complex conditions, but how much unmet medical remains. While more than 7,000 rare diseases have been identified, only 5 percent have treatments. As the majority of these diseases are life threatening, these facts underscore the need for new medicines.

raredisease_bythenumber_sharable.jpgConquering rare diseases presents a variety of unique challenges for scientists and researchers. The underlying causes of rare diseases can be difficult to identity and the symptoms of the diseases are often quite different for each patient, making rare diseases very difficult to diagnose. We now know that more than 80 percent of rare diseases are genetic in origin, giving us greater insights into the biological drivers of many conditions. Progress in understanding some of these diseases at the molecular and genomic level is helping to make new advances possible but for many rare diseases the causes remain elusive.  Even within a particular rare disease, there can be many variations or subtypes resulting in different clinical manifestations and disease progression.

Conducting clinical research in rare diseases is also made more difficult as a result of the practicalities of recruiting and enrolling very small populations of patients. Although a rare disease is generally defined as affecting fewer than 200,000 people in the United States, research suggests that the median population size for rare diseases is actually fewer than 10,000 patients.

The Orphan Drug Act continues to be an important force in driving treatment innovation for rare diseases. More than 575 orphan drugs have been approved since its passage in 1983. In contrast, the FDA had approved fewer than 10 orphan drugs in all of the 1970s before the Act was passed. Unprecedented scientific potential, combined with appropriate incentives, make this a promising time for many patients with rare diseases.

At the same time, we also believe that enhancements to regulatory science offer to accelerate and add clarity to the research and development of treatments for rare diseases, as well as the FDA review of innovative treatments. Advancing the use of patient-focused drug development tools, novel clinical trial designs, and emerging, qualified biomarkers can help reduce uncertainty in the drug development process and ensure that researchers are incorporating the patient perspective into each aspect of the development and review of new medicines.

The biopharmaceutical industry is committed to advancing novel therapies for the more than 30 million Americans suffering from a rare disease today. Together with stakeholders across the rare disease community, biopharma scientists and other researchers are working to overcome often significant research and development challenges to drive innovative options for patients. There are more than 560 medicines currently in development for rare diseases, including more than 150 for rare forms of cancer.raredisease_medicinesindev_sharable.jpg

Learn more about progress in rare disease research here.

Be sure to check the Catalyst this week as we’ll be spotlighting perspectives from the rare disease community.

Anne McDonald Pritchett PhD

Anne McDonald Pritchett, Ph.D., is Senior Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). Her primary focus is overseeing the development of legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, and other issue areas impacting the environment for innovation. In addition to her public policy work, she and her team lead the development of a range of educational and other materials focused on explaining the R&D process, the value of innovation, and the role and contributions of the innovative biopharmaceutical industry.

Anne McDonald Pritchett PhD

World Sickle Cell Day: Recognizing the promise of gene therapy

June 19, 2026

Celebrating rare disease innovation: Progress and the path forward

February 27, 2026

Advancing patient care: A look at new medicines approved in 2025

January 30, 2026

4 things to know on Rare Disease Day

February 28, 2025

Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024

February 3, 2025

Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day

February 29, 2024

Don't close the door on rare disease research

November 13, 2023

New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines

June 22, 2023

Setting the record straight on accelerated approval

May 22, 2023

Celebrating 40 years of the Orphan Drug Act on Rare Disease Day

February 28, 2023

Recognizing National Sickle Cell Awareness Month

September 23, 2022

Biopharmaceutical research and development has ushered in a decade of innovation in rare disease

February 28, 2022

New Report: Nearly 800 new medicines in development to treat rare diseases

December 16, 2021

3 things to know about the importance of post-approval research and development

December 6, 2021

Rare Disease Day 2020: Progress toward cures

February 24, 2020

Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years

November 21, 2019

Pelosi’s radical plan would leave patients with sickle cell disease behind

November 14, 2019

Pelosi’s radical plan would leave patients with rare pediatric diseases behind

November 7, 2019

ICYMI: Fighting for a cure to ALS

September 25, 2019

New report shows nearly 20 innovative medicines in development for sickle cell disease

April 2, 2019

Guest post: Hearing from patients on Rare Disease Day

February 28, 2019

Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation

February 28, 2019

Putting 2018 medicine approvals in context

January 23, 2019

ICYMI: Orphan drug development brings unique challenges

May 21, 2018

Rare Disease Day: Unmet need inspires innovation

February 28, 2018

Guest Post: Debra of America on Epidermolysis Bullosa

March 3, 2017

Guest Post: Room for optimism in ALS research

March 3, 2017

Guest Post: A Cure for Ellie on Leukodystrophy-LBSL

March 2, 2017

Guest Post: Epilepsy Foundation on rare diseases

March 1, 2017

Rare Disease Day: Accelerating innovation for patients in need

Rare Diseases

Rare Disease Day: Accelerating innovation for patients in need

February 28, 2017

Rare Disease Day: Accelerating innovation for patients in need

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list